Perspective Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 119
- Market Cap
- $1B
- Introduction
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase 1
Recruiting
- Conditions
- Pancreatic Ductal AdenocarcinomaGastric CancerEsophageal CancerColorectal CancerHead and Neck CancerOvarian Cancer
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Perspective Therapeutics
- Target Recruit Count
- 112
- Registration Number
- NCT06710756
- Locations
- 🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma
Phase 1
Recruiting
- Conditions
- Melanoma (Skin)Metastatic MelanomaMelanoma Stage IVMucosal MelanomaMelanoma Stage III
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Perspective Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT05655312
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Biogenix Molecular, Miami, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Phase 1
Recruiting
- Conditions
- Neuroendocrine TumorsNeuroendocrine Tumor of the LungNeuroendocrine Tumor of PancreasNeuroendocrine Carcinoma MetastaticNeuroendocrine Tumor CarcinoidCarcinoid Tumor of GI SystemCarcinoid TumorParagangliomaPheochromocytomaSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Perspective Therapeutics
- Target Recruit Count
- 280
- Registration Number
- NCT05636618
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Biogenix Molecular, Miami, Florida, United States
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
Phase 1
Completed
- Conditions
- Melanoma (Skin)Melanoma Stage IVMelanoma, UvealMelanoma, Mucosal
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Perspective Therapeutics
- Target Recruit Count
- 7
- Registration Number
- NCT04904120
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath